JSH 10 Single Topic Conference Program

November 21st (Wednesday) 1st Day

8:30-8:40　　 Opening Remarks

8:40-10:40 　　Session 1　Cutting Edge Molecular Virology of HCV
Chairs: Thomas F. Baumert (Strasbourg) & Kunitada Shimotohno (Chiba)
1. Thomas F. Baumert (Strasbourg): Hepatitis C Virus Entry – Impact for Liver Disease and Antiviral Therapy
2. Yoshiharu Matsuura (Osaka): miR122 Expression and Lipid Metabolism Participate in the Cell Tropism of Hepatitis C Virus Infection
3. Susan L. Uprichard (Chicago): The Niemann-Pick C1-Like 1 Cholesterol Absorption Receptor: a Novel Anti-HCV Therapeutic Target
4. Takaji Wakita (Tokyo): Independent Evolution of Multi-dominant Viral Genome Species of Hepatitis C Virus

10:40-11:00　　 Coffee Break

11:00-11:50 　　Special Lecture 1
Chair: Tatsuo Miyamura (Tokyo)
Ralph Bartenschlager (Heidelberg): Molecular and Cellular Virology of the Hepatitis C Virus: An Update

12:00-12:55　<at Room 1>
Luncheon Seminar 1　sponsored by Mitsubishi Tanabe Pharma Corporation
Chair: Takeshi Okanoue (Osaka)
Kazuaki Chayama (Hiroshima): Treatment of Chronic HCV Genotype 1B-Infected Patients with PEG-IFN/ RIBAVIRIN/TELAPREVIR Triple Therapy

12:00-12:55　<at Room 2>
Luncheon Seminar 2　sponsored by Eisai Co., Ltd. / Minophagen Pharmaceutical Co., LTD.
Chair: Norihiro Kokudo (Tokyo)
1. Kenji Ikeda (Tokyo): Strategy of Elderly and Advanced Stages of Chronic Hepatitis C
2. Wei Tang (Tokyo): The Evaluation on Diagnosis of Hepatocellular Carcinoma in China: Future Perspectives on Des-γ-carboxyprothrombin

13:00-15:15　　 Session 2　Metabolic Aspects of Hepatitis C
Chairs: Francesco Negro (Geneva) & Kazuhiko Koike (Tokyo)
Keynote Lecture
1. Francesco Negro (Geneva): Metabolic Aspects of Hepatitis C Virus Infection Clinical
2. Takumi Kawaguchi (Fukuoka): Hepatitis C and Diabetes
3. Chia-Yen Dai (Taipei): Hepatitis C and Lipid Metabolism Basic
4. Ikuo Shoji (Hyogo): Molecular mechanism of hepatitis C virus-induced Glucose Metabolism Disorder
5. Masaaki Korenaga (Chiba): Iron Metabolism in Hepatitis C

15:20-16:30　　 Poster Presentation & Discussion with Coffee

16:35-17:55 　　Session 3　Hepatitis C in Asia
Chairs: Teerha Piratvisuth (Hat Yai) & Yutaka Sasaki (Kumamoto)
1. Teerha Piratvisuth (Hat Yai): Hepatitis C in Thailand
2. Deepak Amarapurkar (Mumbai): Hepatitis C in India
3. Junko Tanaka (Hiroshima): Hepatitis C in Japan
4. Hyo-Suk Lee (Seoul): Hepatitis C in Korea

18:00-18:55　　 Evening Seminar　sponsored by Chugai Pharmaceutical Co., Ltd.
Chair: Hajime Takikawa (Tokyo)
1. Atsushi Tanaka (Tokyo): JSH Guidelines for the Management of Hepatitis C Virus Infection
2. Yasuhiro Asahina (Tokyo): Risk for HCC and Efficacy of Peginterferon α 2a Monotherapy for Preventing HCC Development in Chronic Hepatitis C Virus Infection

19:00-21:00　　 Conference Welcome Reception

November 22nd (Thursday) 2nd Day
8:00-8:50　　 Morning Seminar　sponsored by Otsuka Pharmaceutical Co., Ltd.
Chair: Hiroshi Yotsuyanagi (Tokyo)
Takehiro Okabayashi (Kochi): Peri-operative Nutritional Support in Hepatic Resection Patients

9:00-10:40 <at Room 1>
Session 4　Pathogenesis of HCV-associated HCC
Chairs: Pei-Jer Chen (Taipei) & Osamu Yokosuka (Chiba)
1. Taro Yamashita (Ishikawa): Cancer Stem Cells in Hepatocarcinogenesis
2. Pei-Jer Chen (Taipei): HCC and Sex Hormones
3. Takeya Tsutsumi (Tokyo): Mitochondria and Pathogenesis of HCV-associated HCC 4. Naoya Kato (Tokyo): Genome Wide Association Studies for HCV-Induced Liver Cirrhosis and Hepatocellular Carcinoma

9:00-11:05 <at Room 2>
Session 5　Diagnosis and Treatment of HCV-associated HCC
Chairs: Masatoshi Kudo (Osaka) & Do Young Kim (Seoul)
1. Ryosuke Tateishi (Tokyo): Survey System and Treatment for Early HCC in Hepatitis C
2. Do Young Kim (Seoul): How to Improve Therapeutic Outcomes of Intermediate / Advanced Stage HCC
3. Shi-Ming Lin (Taipei): Treatment of HCC in Taiwan
4. Shuhei Nishiguchi (Hyogo): Prevention of HCC by IFN Therapy in Chronic Hepatitis C (CHC), and Especially Patients with Low Platelets Counts
5. Hitoshi Yoshiji (Nara): Chemoprevention of HCV-associated HCC by BCAA and ACE-inhibitor

11:05-11:15 　　Coffee break

11:15-11:55 Distinguished Poster Presentation
Chairs: Nobuyuki Enomoto (Yamanashi) & Hidetsugu Saito (Tokyo)
TBA

12:00-12:55 <at Room 1>
Luncheon Seminar 3　sponsored by MSD K.K.
Chair: Sumio Watanabe (Tokyo)
Tetsuo Takehara (Osaka): Impact of Liver Injury on Hepatocarcinogenesis in Chronic Hepatitis C

12:00-12:55 <at Room 2>
Luncheon Seminar 4　sponsored by Ajinomoto Pharmaceuticals Co., Ltd.
Chair: Michio Imawari (Tokyo)
Hisataka Moriwaki (Gifu): Nutraceutical Treatment of Decompensated Liver Cirrhosis

13:00-15:05 　　Session 6　Forefront of Antiviral Treatment for Hepatitis C
Chairs: Jacob George (Sydney) & Namiki Izumi (Tokyo)
1. Michael P. Manns (Hannover): Hepatitis C Treatment in the Era of DAA
2. Kazuaki Chayama (Hiroshima): Successful Therapy with the NS5A Inhibitor and NS3 Protease Inhibitor or to Chronic HCV Genotype 1B-Infected Patients
3. Yasuhiro Asahina (Tokyo): Association of Gene Expression Involving Innate Immunity and IFN Signaling with Genetic Variation in IL28B in Patients with Chronic Hepatitis C
4. Jacob George (Sydney): Host Factors Influencing Antiviral Therapy for Hepatitis C 5. Yasuhito Tanaka (Aichi): Role of IFN-λ on Antiviral Therapy for Hepatitis C

15:10-16:00　　 Special Lecture 2
Chair: Shuichi Kaneko (Ishikawa)
Osamu Takeuchi (Kyoto): Recognition of Viral Infection by Innate Immunity

16:10-17:50　　 Session 7　Management of Hepatitis C under Special Conditions
Chairs: Ferruccio Bonino (Pisa) & Masashi Mizokami (Chiba)
1. Jia-Horng Kao (Taipei): Coinfection with HBV
2. Ferruccio Bonino (Pisa): Coinfection with HBV
3. Jürgen K. Rockstroh (Bonn): Hepatitis C Coinfection with HIV
4. Yasuhiko Sugawara (Tokyo): Prevention of HCV Hepatitis Recurrence after Liver Transplantation

17:50-18:00 　　Closing Remarks